Liraglutide vs Retatrutide
Overview
Liraglutide and Retatrutide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Liraglutide and Retatrutide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Liraglutide | Retatrutide | |
|---|---|---|
| Category | Weight Management & Metabolic | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | Research use only |
| Typical dosage | 0.6-3.0 mg | Clinical trials |
| Frequency | daily | weekly |
| Reported benefits | Weight loss, blood sugar control, cardiovascular protection | Enhanced weight loss beyond dual agonists, metabolic improvement |
| Reported side effects | Nausea, GI disturbances, potential pancreatitis | Clinical trial phase |
Key differences
Primary use. Liraglutide is categorised under Weight Management & Metabolic, while Retatrutide falls under Weight Management & Metabolic. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Liraglutide: FDA-approved. Retatrutide: not FDA-approved; treated as a research compound.
Dosing. Liraglutide is typically dosed at 0.6-3.0 mg (daily). Retatrutide is typically dosed at Clinical trials (weekly).
Can you stack them?
Some protocols combine peptides, but stacking Liraglutide and Retatrutide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Liraglutide and Retatrutide?
- Liraglutide and Retatrutide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status. Liraglutide is FDA-approved for one or more indications, whereas Retatrutide is not FDA-approved; generally classified as a research compound.
- What is Liraglutide used for?
- FDA-approved GLP-1 for weight loss.
- What is Retatrutide used for?
- Investigational triple agonist (GIP/GLP-1/glucagon). TRIUMPH-1 Phase 3 (May 2026): 28.3% body weight loss at 80 weeks. FDA submission anticipated Q3–Q4 2026.
- Can you take Liraglutide and Retatrutide together?
- Some users combine peptides within a single protocol, but stacking Liraglutide and Retatrutide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Liraglutide or Retatrutide FDA-approved?
- Liraglutide is FDA-approved for one or more indications. Retatrutide is not FDA-approved; generally classified as a research compound.
Read the full articles
- Liraglutide — full monograph: mechanism, research, dosing & references
- Retatrutide — full monograph: mechanism, research, dosing & references